[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645339":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":36,"centralContacts":40,"locations":32,"responsibleParty":46,"collaborators":32,"id":48,"slug":32,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":32,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":32,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":68,"whyStopped":32,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":32},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Ubrogepant-Part 1-Dose A","EXPERIMENTAL","Participants will receive a single oral dose A of ubrogepant on Day 1 under fasting conditions.",[13],"Drug: Ubrogepant",{"label":15,"type":10,"description":16,"interventionNames":17},"Ubrogepant-Part 1-Dose B","Participants will receive a single oral dose B of ubrogepant on Day 1 under fasting conditions.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Ubrogepant-Part 2-Dose C","Participants will receive a single oral dose C of ubrogepant on Day 1 under fasting conditions.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Ubrogepant-Part 2-Dose D","Participants will receive a single oral dose D of ubrogepant on Day 1 under fed conditions.",[13],[27,33],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Ubrogepant","IRT Oral Tablet",[15],null,{"type":28,"name":29,"description":34,"armGroupLabels":35,"otherNames":32},"ODT Oral Tablet",[9,19,23],[37],{"name":38,"affiliation":5,"role":39},"ABBVIE INC.","STUDY_DIRECTOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":32,"email":45},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",{"type":47,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100645339",false,"NCT07680686","Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants","A Two-Part, Phase 1, Open-Label, Randomized Study to Evaluate the Relative Bioavailability (Versus Immediate Release Tablet) and Food Effect of a New Orally Disintegrating Tablet Formulation of Ubrogepant in Healthy Volunteers","Inclusion Criteria:\n\n* BMI is ≥ 18.0 to ≤ 32.0 kg\u002Fm2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.\n\nExclusion Criteria:\n\n* History: of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic, neurologic, or psychiatric disease or disorder, history of Raynaud's Phenomenon, or any uncontrolled medical illness.\n* History of any clinically significant sensitivity or allergy to any medication or food.",true,"ALL","18 Years","55 Years",{"count":59,"type":60},52,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.",[66],"Healthy Volunteer",[66,29],"NOT_YET_RECRUITING","2026-06-26",{"date":71,"type":72},"2026-07-02","ACTUAL",{"date":74,"type":60},"2026-06-30",{"date":76,"type":60},"2026-10",{"name":5,"class":6}]